Clinical Trials in Tennessee

Showing 4801-4820 of 20,239 trials

An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment

NCT01506141

This extension study of HGT-HIT-045 is designed to collect long-term safety data in pediatric participants with Hunter syndrome and cognitive impairment who are receiving intrathecal (IT) idursulfase-IT and intravenous (IV) Elaprase enzyme replacement therapy.

Hunter Syndrome

Takeda15 participantsStarted Aug 2010

Chicago, Illinois, United States • Chapel Hill, North Carolina, United States • Portland, Oregon, United States +6 more locations

TERMINATEDPhase 2/329 miles

Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

NCT04857359

This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.

Parkinson DiseaseDyskinesia, Drug-InducedDyskinesias

Addex Pharma S.A.25 participantsStarted Aug 2021

Phoenix, Arizona, United States • Fresno, California, United States • Irvine, California, United States +38 more locations

An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment

Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

Find Trials by Condition in Tennessee

Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

Suction Versus Water Seal for Initial Treatment of Traumatic Pneumothorax Trial

Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

The Symptomatic Cerebral Cavernous Malformation Trial of REC-994

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer